Pharmacosmos, an international healthcare company specializing in iron- and carbohydrate-based treatments and solutions for human and animal use, today announces it has entered into an exclusive agreement with Pfizer Inc., one of the world’s premier biopharmaceutical companies, whereby Pfizer acquires the exclusive commercialisation rights to Monofer® in Brazil. Monofer® is an innovative intravenous iron replacement therapy for the treatment of iron deficiency with or without anaemia (IDA).
According to the World Health Organization (WHO), iron deficiency is the most common and widespread nutritional disorder in the world, affecting approximately 2 billion people. Although the condition affects a large number of children and women in developing countries, it is the only nutrient deficiency which is also significantly prevalent in industrialized countries. Major health consequences include poor pregnancy outcome, impaired physical and cognitive development, increased risk of morbidity in children and reduced work productivity in adults. Anaemia contributes to 20% of all maternal deaths.
With a population of more than 200 million it is expected that the market for iron deficiency treatments in Brazil will grow significantly over the coming years.
“Pfizer is pleased to partner with Pharmacosmos and looks forward to leveraging our expertise and resources to make this important treatment option for iron deficiency available to patients throughout Brazil. This agreement will increase our Hospital Business portfolio” said Victor Mezei, Pfizer Brazil Country Manager.
“We are very much looking forward to working with Pfizer in Brazil and believe that Monofer® will serve yet unmet clinical needs with potential to reduce the health problems of iron deficiency patients in Brazil. Our agreement with Pfizer is an important milestone in our ambition to establish Monofer® as a category leading brand,” says Vice President in Pharmacosmos, Michael Ryde.
Additional details of the agreement were not disclosed.
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizer.com. In addition, to learn more, please visit us on www.pfizer.com and follow us on Twitter at @Pfizer and @PfizerNews, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
Monofer® (10% iron isomaltoside 1000) is an iron-carbohydrate complex for intravenous administration. Monofer® is already marketed in more than 30 countries, primarily in Europe, for the treatment of iron deficiency anaemia. Monofer® is under development in the rest of the world, including North America and Japan. Monofer® is manufactured by Pharmacosmos, Denmark.
Headquartered in Denmark, Pharmacosmos is a family-owned, international healthcare company with more than 50 years of innovation and leadership in iron- and carbohydrate-based treatments and solutions for human and animal use.
A research-based company, its ongoing R&D programme focuses on improving the lives of patients with iron deficiency with or without anaemia. More than 1 billion people live with iron deficiency anaemia and it is the leading cause of death for an estimated 180,000 people every year. This makes it one of the largest global health challenges of our time.
Pharmacosmos has subsidiaries in the Nordics, Germany, UK and US and its products are marketed in more than 80 countries across the world. Its manufacturing facilities are approved, among others, by the Danish Medicines Agency and the US FDA.
You are now leaving Pharmacosmos.com. The website you are about to visit is is a Pharmacosmos subsidary. Do you want to proceed?